Table 7.6a

Immunosuppression Use for Induction, 1995 to 2004

Recipients with Pancreas After Kidney (PAK) Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 67 113 130 157 221 303 307 377 343 419
With Immunosuppression Info 67 109 129 152 218 297 305 374 335 403
Induction Drugs 40.3% 0.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 7.5% 45.9% 48.1% 19.7% 8.3% 1.7% 0.3% 2.4% 0.6% 1.5%
OKT3 40.3% 29.4% 24.8% 15.1% 8.7% 3.0% 0.7% 1.3% 0.9% 0.2%
Thymoglobulin 0.0% 0.0% 0.0% 0.7% 30.3% 37.4% 50.2% 51.6% 50.7% 57.6%
Zenapax 0.0% 0.0% 0.0% 26.3% 36.7% 32.7% 33.1% 25.1% 9.3% 6.7%
Simulect 0.0% 0.0% 0.8% 9.9% 10.6% 17.2% 13.1% 8.3% 8.1% 5.5%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 13.4% 19.4%
No Induction Drugs Recorded 13.4% 28.4% 26.4% 36.8% 33.5% 33.0% 25.6% 27.5% 26.3% 19.6%


Source: OPTN/SRTR Data as of May 2, 2005.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.